#ACRbest Abstracts – Day 2 Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNows #ACRbest abstract reports from Monday, 11/13 at #ACR23. https://t.co/yIYYI7IVBD https://t.co/86Nt1mVha8

Monitoring the Effect of Upadacitinib Therapy with a Smart Watch? https://t.co/z6durHZ57R https://t.co/wSJiWNOx9M

Lupus Topic Panel Featuring panelists Dr. Kathryn Dao, Eric Dein and Sheila Reyes, discussing the best and most interesting lupus studies presented at #ACR23. https://t.co/QWR17kOkHD https://t.co/jpaUI2X2Fc

Will CAR T Cells also treat RA? Dr. Jonathan Kay reports on abstract 0424 from #ACR23 https://t.co/xPMmVNZdAC https://t.co/8b3AmjzvML

Methotrexate: shall we split up? Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg. https://t.co/txCIkgtvzP https://t.co/Mk8FLy4jO3

How do we manage difficult discussions about pregnancy in RA? Most rheums know that it is important to get pregnancy planning right for women of childbearing age living with rheumatic diseases. That is easier said than done, though... https://t.co/cXtqqVv6fp https://t.co/k5afTUKYf8

L20 at #ACR23 Phase 3 RCT of #Telitacicept vs. placebo in #RA ☝🏻B-cell neutralization by targeting BlyS and APRIL ✅ better ACR20 and 50 response at W24 ✅ favorable structural response ✅ good safety profile ❓ few seronegative patients A new small molecule to treat #RA? PAJ https://t.co/fyrqAya41e

#ACR23 #EdLovering presenting on association b/w #RA, #CVD & #Dementia: 👉🏻CVD is not a signif mediator b/w RA &Dementia 👉🏻 signif synergy b/w RA & CVD on dementia (HR 2.45 vs those w/o RA&CVD) 👉🏻 ⬆️ risk of dementia in RA mostly in people with RA+CVD #Mayoclinicrheumatology https://t.co/5kqs3HAACn

The dynamic Dr. Vinod Chandran, talking about metabolomics in #psoriaticDisease #ACR23 The metabolomics facility was established recently at the @UHN @UofT @SchroederInst and we are already seeing the results. @KrembilF @CRASCRRheum @UofTRheum https://t.co/Azxq3k8w5g

Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target trial emulation. Congrats to the authors on plenary presentation! #ACR23 https://t.co/P7keAoOX7M

🔥 HOT OFF THE PRESS for #ACR23 Effectiveness of a fourth dose of #COVID19 mRNA #vaccine in patients with systemic autoimmune rheumatic diseases using DMARDs: an emulated target trial https://t.co/bvc75BP4aG @zach_wallace_md @jeffsparks https://t.co/CAlgjvUr9X